Neuraxpharm Group has launched Riulvy (tegomil fumarate) in Germany, marking the first European introduction of the next-generation oral fumarate therapy for relapsing-remitting multiple sclerosis (RRMS). The company plans further rollouts across Europe in the coming months.

Tegomil fumarate is designed to provide equivalent efficacy to existing fumarate treatments while improving gastrointestinal tolerability, a common concern with older oral therapies. The therapy is approved for use in adults and adolescents aged 13 and above. By addressing tolerability, Riulvy aims to support long-term adherence and offer neurologists more flexible treatment options for managing RRMS.

Dr Jörg-Thomas Dierks, chief executive officer of Neuraxpharm, said: “This launch in Germany represents another significant achievement in our mission to bring innovative therapies to people living with CNS disorders. We now add a new oral fumarate therapy to our expanding multiple sclerosis portfolio which offers patients and neurologists more flexible, differentiated options in MS management.”

Multiple sclerosis affects around 2.8 million people globally, with Europe showing a higher prevalence than the global average — approximately 133 per 100,000 people. Germany has one of the highest prevalence rates in Europe at 300 per 100,000. The launch of Riulvy reflects Neuraxpharm’s commitment to broadening treatment options for MS patients and supporting physicians with therapies that are easier to tolerate over long-term use.

The product is a co-development with the Tiefenbacher Group and received European Commission marketing authorisation in July 2025. Germany was chosen as the first European market for launch, with additional countries to follow as part of Neuraxpharm’s European expansion strategy.

Riulvy adds to Neuraxpharm’s multiple sclerosis portfolio, complementing existing treatments and aligning with the company’s broader focus on central nervous system disorders. By improving tolerability and supporting adherence, the therapy has the potential to enhance patient outcomes and reduce treatment discontinuation rates commonly associated with gastrointestinal side effects in oral fumarate therapies.

The launch also underscores the ongoing trend in neurology toward next-generation oral therapies that balance efficacy and tolerability, offering patients more convenient options while maintaining disease control. Neuraxpharm’s strategic approach reflects its commitment to addressing unmet needs in CNS disorders across Europe.